Haima Therapeutics

📍 Cleveland, United States🗓 Founded 2016👥 14 employees💰 Last funded May 2025
Biotechnology🌐 haimatherapeutics.com
Website LinkedIn
Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Haima Therapeutics?
Haima Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Haima Therapeutics last raise funding?
The most recent investment in Haima Therapeutics recorded on gritt.io was in May 2025.
When was Haima Therapeutics founded?
Haima Therapeutics was founded in 2016.
What industry is Haima Therapeutics in?
Haima Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Haima Therapeutics based?
Haima Therapeutics is headquartered in Cleveland, United States.